Press Releases

Taxotere Approved for Treatment of Oral and Head and Neck Cancer

October 1, 2006

"This study has shown that induction therapy with a Taxotere, cisplatin, fluorouracil (TPF) regimen increases survival. With this approval, I hope to see TPF become the standard of care for induction therapy for patients with this type of cancer." - Marshall Poser, MD, Medical Director

click here for Details of FDA Announcement